BACTIFLOX 750 Lactab Price
Active Substance: Ciprofloxacin (as HCl).
Overview
Welcome to Dwaey, specifically on BACTIFLOX 750 Lactab page.
This medicine contains an important and useful components, as it consists of
Ciprofloxacin (as HCl)is available in the market in concentration
Name
Ciprofloxacin 0.3% E&E prep
Precaution
Prolonged use of Ciprofloxacin may result in overgrowth of nonsusceptible organisms including fungi. Ciprofloxacin should be discontinued at the first appearance of a skin rash or any other sign of hypersensitivity reaction. Not for injection into the eye. Lactation: Drug is distributed into milk; use with caution
Indication
Otitis media, Superficial ophthalmic infections, Otitis externa
Contra indication
Ciprofloxacin is contraindicated in patients who have hypersensitivity to Ciprofloxacin or other quinolones.
Side Effect
>10% Burning,Ciprofloxacin precipitate in superficial portion of corneal defect,Stinging 1-10% Conjunctival hyperemia,Crystals or scales on eyelashes,Foreign-body sensation,Itching,Keratopathy or keratitis,Lid margin crusting,Unpleasant taste after instillation <1% Corneal infiltrates,Corneal staining,Decrease in vision,Lid edema,Ocular discomfort,Photophobia,Sensitivity reactions,Tearing
Pregnancy Category ID
3
Mode of Action
Ciprofloxacin promotes breakage of double-stranded DNA in susceptible organisms and inhibits DNA gyrase, which is essential in reproduction of bacterial DNA.
Interaction
May increase plasma concentrations of CYP1A2 substrates (e.g. clozapine, ropinirole, theophylline). Enhances effect of oral anticoagulants (e.g. warfarin) and glibenclamide. Increased toxicity of methotrexate. Plasma concentrations may be increased by probenecid. Reduced absorption w/ oral multivitamins and mineral supplements containing divalent or trivalent cations (e.g. Fe, Zn, Ca) and antacids containing Al, Ca or Mg. Concomitant use w/ class IA antiarrhythmics (e.g. quinidine, procainamide), class III antiarrhythmics (e.g. amiodarone, sotalol), TCAs, macrolides and antipsychotics may result in additive effects on QT interval prolongation. Concurrent use w/ corticosteroids may increase risk of severe tendon disorders. Increased risk of CNS stimulation w/ NSAIDs. Altered serum concentrations of phenytoin. Potentially Fatal: Marked elevation in serum levels of tizanidine which is associated w/ potentiated hypotensive and sedative effect.
Pregnancy Category Note
Information not available
Adult Dose
Information not available
Child Dose
Information not available
Renal Dose
Information not available
Administration
Information not available
